WO2002094254A3 - Abuse resistant pharmaceutical composition containing capsaicin - Google Patents
Abuse resistant pharmaceutical composition containing capsaicin Download PDFInfo
- Publication number
- WO2002094254A3 WO2002094254A3 PCT/US2002/015553 US0215553W WO02094254A3 WO 2002094254 A3 WO2002094254 A3 WO 2002094254A3 US 0215553 W US0215553 W US 0215553W WO 02094254 A3 WO02094254 A3 WO 02094254A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- pharmaceutical composition
- capsaicin
- composition containing
- abuse resistant
- Prior art date
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 title abstract 6
- 229960002504 capsaicin Drugs 0.000 title abstract 3
- 235000017663 capsaicin Nutrition 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 5
- 239000004615 ingredient Substances 0.000 abstract 2
- 239000000945 filler Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60231298T DE60231298D1 (en) | 2001-05-23 | 2002-05-16 | CAPSAICIN-CONTAINING MISAMENTARY PHARMACEUTICAL COMPOSITIONS |
JP2002590972A JP4315687B2 (en) | 2001-05-23 | 2002-05-16 | Abuse-preventing pharmaceutical composition containing capsaicin |
AU2002309885A AU2002309885B2 (en) | 2001-05-23 | 2002-05-16 | Abuse resistant pharmaceutical composition containing capsaicin |
CA002447807A CA2447807C (en) | 2001-05-23 | 2002-05-16 | Abuse resistant pharmaceutical composition containing capsaicin |
EP02736910A EP1392270B1 (en) | 2001-05-23 | 2002-05-16 | Abuse resistant pharmaceutical composition containing capsaicin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29280901P | 2001-05-23 | 2001-05-23 | |
US60/292,809 | 2001-05-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002094254A2 WO2002094254A2 (en) | 2002-11-28 |
WO2002094254A3 true WO2002094254A3 (en) | 2003-03-27 |
Family
ID=23126288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/015553 WO2002094254A2 (en) | 2001-05-23 | 2002-05-16 | Abuse resistant pharmaceutical composition containing capsaicin |
Country Status (10)
Country | Link |
---|---|
US (1) | US20030064122A1 (en) |
EP (1) | EP1392270B1 (en) |
JP (2) | JP4315687B2 (en) |
CN (1) | CN1511030A (en) |
AT (1) | ATE423556T1 (en) |
AU (1) | AU2002309885B2 (en) |
CA (1) | CA2447807C (en) |
DE (1) | DE60231298D1 (en) |
ES (1) | ES2321589T3 (en) |
WO (1) | WO2002094254A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572779B2 (en) | 2010-12-22 | 2017-02-21 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170181A1 (en) * | 1999-04-06 | 2003-09-11 | Midha Kamal K. | Method for preventing abuse of methylphenidate |
WO2003004032A1 (en) * | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
PL207748B1 (en) * | 2001-07-06 | 2011-01-31 | Penwest Pharmaceuticals Company | Sustained release formulations of oxymorphone |
US7157103B2 (en) * | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US7141250B2 (en) * | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
JP2005523876A (en) * | 2001-09-26 | 2005-08-11 | ペンウェスト ファーマシューティカルズ カンパニー | Opioid formulations with reduced potential for abuse |
EP1450824A4 (en) * | 2001-11-02 | 2005-09-28 | Elan Corp Plc | Pharmaceutical composition |
WO2003092676A1 (en) * | 2002-04-29 | 2003-11-13 | The General Hospital Corporation | Compositions and methods for preventing abuse of orally administered medications |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20040109886A1 (en) * | 2002-08-27 | 2004-06-10 | Larry Rigby | Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent |
ES2677769T3 (en) * | 2002-09-20 | 2018-08-06 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and procedures |
WO2004026262A2 (en) * | 2002-09-23 | 2004-04-01 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
DE10250084A1 (en) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
DE602004024963D1 (en) | 2003-03-13 | 2010-02-25 | Controlled Chemicals Inc | OXYCODON CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED ACTIVITY |
US8778382B2 (en) * | 2003-04-30 | 2014-07-15 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US8906413B2 (en) * | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
DE102004019916A1 (en) * | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Anti-abuse drug-containing patch |
EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
EP1809259B1 (en) * | 2004-10-15 | 2014-12-03 | Supernus Pharmaceuticals, Inc. | Less abusable pharmaceutical preparations |
US20070231268A1 (en) * | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
EP1879855A2 (en) * | 2005-04-25 | 2008-01-23 | Neurogesx, Inc. | Trpv1 agonist compounds and methods for making and using the same |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
CN104825397A (en) | 2006-04-03 | 2015-08-12 | 伊萨·奥迪迪 | Controlled release delivery device comprising an organosol coat |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
SI2484346T1 (en) * | 2006-06-19 | 2017-05-31 | Alpharma Pharmaceuticals Llc | Pharmaceutical compositions |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
US7645767B2 (en) * | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
JP2010506833A (en) * | 2006-10-11 | 2010-03-04 | アルファーマ,インコーポレイテッド | Pharmaceutical composition |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
WO2008115811A2 (en) * | 2007-03-16 | 2008-09-25 | Endo Pharmaceuticals, Inc. | Transdermal delivery form disposal systems and methods |
WO2008131256A1 (en) * | 2007-04-19 | 2008-10-30 | Trinity Laboratories Inc. | Improved treatments for premature ejaculation in humans |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
EP2224808A4 (en) * | 2007-12-17 | 2013-11-27 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
CA2709905A1 (en) * | 2007-12-17 | 2009-06-25 | Alfred Liang | Abuse-resistant oxycodone composition |
JP5651818B2 (en) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | Controlled release formulation to prevent misuse |
RU2493830C2 (en) | 2008-01-25 | 2013-09-27 | Грюненталь Гмбх | Drug form |
BRPI0912014A2 (en) | 2008-05-09 | 2019-03-06 | Grünenthal GmbH | A process for preparing an intermediate powder formulation and a final solid dosage form using a spray freeze step |
WO2010069050A1 (en) | 2008-12-16 | 2010-06-24 | Labopharm Inc. | Misuse preventative, controlled release formulation |
WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
JP2012533585A (en) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant dosage forms for oxidation-sensitive opioids |
BR112012001547A2 (en) | 2009-07-22 | 2016-03-08 | Gruenenthal Gmbh | hot melt extruded pharmaceutical dosage form |
EP3064064A1 (en) * | 2009-09-30 | 2016-09-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
WO2012028319A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US9233073B2 (en) | 2010-12-23 | 2016-01-12 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
CN103857386A (en) | 2011-07-29 | 2014-06-11 | 格吕伦塔尔有限公司 | Tamper-resistant tablet providing immediate drug release |
BR112014002022A2 (en) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | tamper-resistant tablet providing immediate drug release |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
AU2013248351B2 (en) | 2012-04-18 | 2018-04-26 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
MX366159B (en) | 2012-11-30 | 2019-07-01 | Acura Pharmaceuticals Inc | Self-regulated release of active pharmaceutical ingredient. |
EA201500742A1 (en) | 2013-02-05 | 2015-12-30 | Пердью Фарма Л.П. | PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE |
US10092528B2 (en) | 2013-03-13 | 2018-10-09 | Altria Client Services Llc | Application of encapsulated capsaicin and analogues thereof for controlling calorie intake |
US9517208B2 (en) | 2013-03-15 | 2016-12-13 | Purdue Pharma L.P. | Abuse-deterrent dosage forms |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
MX2015016254A (en) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Tamper resistant dosage form with bimodal release profile. |
BR112015026549A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-proof dosage form containing one or more particles |
AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
WO2015145459A1 (en) | 2014-03-26 | 2015-10-01 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release coated reservoir solid dosage form |
MX2016014738A (en) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol. |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
EP3193873A4 (en) * | 2014-09-15 | 2018-05-30 | Inspirion Delivery Technologies, LLC | Orally administrable compositions and methods of deterring abuse by intranasal administration |
AU2016251854A1 (en) | 2015-04-24 | 2017-10-19 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
JP2018526414A (en) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Protection against oral overdose with abuse-inhibiting immediate release formulations |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599342A (en) * | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US4681897A (en) * | 1984-01-16 | 1987-07-21 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898887A (en) * | 1984-12-20 | 1990-02-06 | The Procter & Gamble Company | Compounds and compositions having anti-inflammatory and analgesic activity |
US5383848A (en) * | 1990-04-12 | 1995-01-24 | Gensia, Inc. | Iontophoretic administration of drugs |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5762963A (en) * | 1995-06-07 | 1998-06-09 | Emory University | Method and compositions for controlling oral and pharyngeal pain using capsaicinoids |
US5766623A (en) * | 1996-03-25 | 1998-06-16 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Compactable self-sealing drug delivery agents |
US7157103B2 (en) * | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US7141250B2 (en) * | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US20030068276A1 (en) * | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
-
2002
- 2002-04-08 US US10/118,110 patent/US20030064122A1/en not_active Abandoned
- 2002-05-16 AT AT02736910T patent/ATE423556T1/en not_active IP Right Cessation
- 2002-05-16 ES ES02736910T patent/ES2321589T3/en not_active Expired - Lifetime
- 2002-05-16 WO PCT/US2002/015553 patent/WO2002094254A2/en active Application Filing
- 2002-05-16 JP JP2002590972A patent/JP4315687B2/en not_active Expired - Fee Related
- 2002-05-16 CA CA002447807A patent/CA2447807C/en not_active Expired - Fee Related
- 2002-05-16 EP EP02736910A patent/EP1392270B1/en not_active Expired - Lifetime
- 2002-05-16 AU AU2002309885A patent/AU2002309885B2/en not_active Ceased
- 2002-05-16 CN CNA028103890A patent/CN1511030A/en active Pending
- 2002-05-16 DE DE60231298T patent/DE60231298D1/en not_active Expired - Fee Related
-
2009
- 2009-04-08 JP JP2009094439A patent/JP2009149696A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599342A (en) * | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US4681897A (en) * | 1984-01-16 | 1987-07-21 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
Non-Patent Citations (2)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, BEHM ET AL.: "reducing craving for cigarettes while decreasing smoke intake using capsaicin-enhanced low tar cigarettes", XP002212281, Database accession no. 199598145755 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1996, RISTVEDT ET AL.: "the use of pharmacologic pain sensitization in the treatement of repetitive hair-pulling", XP002212282, Database accession no. nlm8870291 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572779B2 (en) | 2010-12-22 | 2017-02-21 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
Also Published As
Publication number | Publication date |
---|---|
JP2009149696A (en) | 2009-07-09 |
US20030064122A1 (en) | 2003-04-03 |
WO2002094254A2 (en) | 2002-11-28 |
AU2002309885B2 (en) | 2007-11-01 |
JP2005515153A (en) | 2005-05-26 |
DE60231298D1 (en) | 2009-04-09 |
CA2447807A1 (en) | 2002-11-28 |
EP1392270B1 (en) | 2009-02-25 |
JP4315687B2 (en) | 2009-08-19 |
ATE423556T1 (en) | 2009-03-15 |
ES2321589T3 (en) | 2009-06-09 |
CA2447807C (en) | 2009-10-13 |
CN1511030A (en) | 2004-07-07 |
EP1392270A2 (en) | 2004-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002094254A3 (en) | Abuse resistant pharmaceutical composition containing capsaicin | |
GEP20022851B (en) | Flash-Melt Oral Dosage Formulation | |
WO2007009806A3 (en) | Solid dosage formulations of narcotic drugs having improved buccal adsorption | |
SI1685839T1 (en) | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist | |
WO2001032183A3 (en) | Pharmaceutical compositions comprising oxcarbazepine | |
WO2005032474A3 (en) | Pharmaceutical compositions for prevention of overdose or abuse | |
CA2427227A1 (en) | Lactam compound | |
MY144297A (en) | Pharmaceutical compositions | |
MX2007000008A (en) | Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol. | |
WO2001090091A8 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
WO2004000197A3 (en) | Quick dissolve compositions and tablets based thereon | |
BG66093B1 (en) | Controlled release compositions comprising nimesulide | |
MY127350A (en) | Flash-melt oral dose formulations | |
WO2002004421A3 (en) | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics | |
WO2000078294A3 (en) | Oral administration form for administering a fixed tramadol and diclofenac combination | |
MXPA05013392A (en) | Pharmaceutical compositions comprising atorvastatin manufactured without granulation. | |
HK1067299A1 (en) | Pharmaceutical compositions containing terbinafineand use thereof | |
WO2005004860A3 (en) | Novel solid pharmaceutical composition comprising amisulpride | |
CA2423574A1 (en) | Stabilization of solid drug formulations | |
WO2005004915A3 (en) | Compositions comprising meloxicam | |
EP2138175A3 (en) | Formulations comprising valsartan for treating diabetes or microalbuminuria | |
WO2003035080A3 (en) | A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors | |
WO2008079343A3 (en) | Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients | |
CA2442210A1 (en) | Aryl oxime-piperazines useful as ccr5 antagonists | |
BE2016C017I2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002309885 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002736910 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002590972 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2447807 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028103890 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002736910 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref document number: 2002309885 Country of ref document: AU Date of ref document: 20020516 Kind code of ref document: B |